Business Context and Reporting Period
This Form 8-K was filed by Lantheus Holdings, Inc. on December 29, 2017, reporting material events occurring on December 29 and 30, 2017. The filing concerns Lantheus Medical Imaging, Inc. (LMI), the operating subsidiary of the Company, and details amendments to critical supply agreements for nuclear medicine products.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on contractual agreements rather than financial performance data.
Material Changes and Agreements
- NTP Amendment No. 4: On December 29, 2017, LMI amended its Sales Agreement with NTP Radioisotopes (SOC) Ltd. The term was extended from December 31, 2017, to December 31, 2020. The amendment modifies volume purchase requirements and unit pricing for the supply of molybdenum-99 (Mo-99) from NTP and its subcontractor, ANSTO. Specific pricing and volume terms are being requested for confidential treatment.
- Triad Isotopes Extension: On December 30, 2017, LMI entered into a binding extension of its supply agreement with Jubilant Drax Image Radiopharmacies, Inc. d/b/a Triad Isotopes, Inc. Effective January 1, 2018, this agreement extends through December 31, 2020. It covers the supply of TechneLite generators, Xenon, Neurolite, and other products, specifying new pricing levels and volume requirements.
Guidance, Risks, and Contingencies
The filing outlines termination rights for both agreements, which may be triggered by material breach, failure to provide required amounts of Mo-99, bankruptcy, or force majeure events. No forward-looking financial guidance or management commentary regarding future earnings is included in this report.
Investor Verification Checklist
- Verify the specific volume purchase requirements and unit pricing terms for the NTP Amendment No. 4 once disclosed in the Form 10-K.
- Confirm the operational impact of the extended Mo-99 supply chain on production capacity through 2020.
- Review the pricing levels and volume commitments in the extended Triad Isotopes agreement to assess revenue stability.
- Monitor for any force majeure events or supply disruptions that could trigger termination clauses in either agreement.